Mereo BioPharma Group plc (MREO)Healthcare | Biotechnology | London, United Kingdom | NasdaqCM
0.31 USD
-0.01
(-2.790%) ⇩
(Oct. 13, 2026, 2:49 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 11:04 a.m. EDT
The investment case here is defined by extreme binary risk. Fundamentally, the company is in distress with negative earnings, negative free cash flow, and a multi-year price trajectory that has erased nearly half its value. The recent news of failed Phase 3 trials and regulatory uncertainty regarding setrusumab confirms a deteriorating business quality, making the long-term outlook bleak despite the low valuation multiples which reflect this reality. There is no dividend to provide income, and the balance sheet, while currently liquid, is burning cash with no proven product pipeline to sustain operations indefinitely. However, the short-term dynamic is driven entirely by speculative momentum. The options market is screaming 'call,' with heavy positioning in strikes far above the current price, indicating a belief in a sudden, dramatic recovery likely tied to a future catalyst like a successful trial readout or partnership deal. While the statistical forecast model predicts a modest decline over the next 45 days, this is a weak signal compared to the aggressive speculative positioning seen in the options chain. For a trader, this is a high-risk momentum play dependent on a specific event; for an investor, the fundamental rot and lack of sustainable growth make it a poor holding. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.114360 |
| AutoETS | 0.136788 |
| AutoTheta | 0.138792 |
| MSTL | 0.141549 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 5.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.264 |
| Excess Kurtosis | -0.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.595 |
| Market Cap | 48,913,348 |
| Forward P/E | -13.36 |
| Beta | 0.14 |
| Website | https://www.mereobiopharma.com |
As of Oct. 10, 2026, 11:04 a.m. EDT: Speculators are overwhelmingly bullish on the upside, evidenced by massive open interest in out-of-the-money calls at strikes of $1.00 and $2.00 across various expirations, while put activity remains negligible and concentrated only in deep out-of-the-money strikes. This asymmetry suggests a speculative bet on a potential clinical success or regulatory approval rather than a hedge against downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.83928573 |
| Address1 | One Cavendish Place |
| Address2 | 4th Floor |
| All Time High | 8.48 |
| All Time Low | 0.2 |
| Ask | 0.4838 |
| Ask Size | 2 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 1,558,780 |
| Average Daily Volume3 Month | 4,045,801 |
| Average Volume | 4,045,801 |
| Average Volume10Days | 1,558,780 |
| Beta | 0.143 |
| Bid | 0.35 |
| Bid Size | 1 |
| Book Value | 0.18 |
| City | London |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.3063 |
| Current Ratio | 5.884 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.3189 |
| Day Low | 0.2974 |
| Debt To Equity | 3.595 |
| Display Name | Mereo BioPharma |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -32,416,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.655 |
| Enterprise Value | 21,246,594 |
| Eps Current Year | -0.04167 |
| Eps Forward | -0.022920659 |
| Eps Trailing Twelve Months | -0.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.308 |
| Fifty Day Average Change | -0.0016999841 |
| Fifty Day Average Change Percent | -0.0055194288 |
| Fifty Two Week Change Percent | -83.92857 |
| Fifty Two Week High | 2.37 |
| Fifty Two Week High Change | -2.0637 |
| Fifty Two Week High Change Percent | -0.87075955 |
| Fifty Two Week Low | 0.2 |
| Fifty Two Week Low Change | 0.10630001 |
| Fifty Two Week Low Change Percent | 0.53150004 |
| Fifty Two Week Range | 0.2 - 2.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,556,112,600,000 |
| Float Shares | 125,023,660 |
| Forward Eps | -0.022920659 |
| Forward P E | -13.363491 |
| Free Cashflow | -13,656,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 39 |
| Fullday Change | -0.008899987 |
| Fullday Change Percent | -2.7899647 |
| Fullday Price | 0.3063 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -1,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0074699996 |
| Held Percent Institutions | 0.35467997 |
| Implied Shares Outstanding | 159,690,973 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom. |
| Long Name | Mereo BioPharma Group plc |
| Market | us_market |
| Market Cap | 48,913,348 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_307970474 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -28,099,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 54,734,079 |
| Number Of Analyst Opinions | 5 |
| Open | 0.3112 |
| Operating Cashflow | -25,346,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 44 33 3023 7300 |
| Previous Close | 0.3152 |
| Price Eps Current Year | -7.3506126 |
| Price Hint | 4 |
| Price To Book | 1.7016667 |
| Price To Sales Trailing12 Months | Infinity |
| Profit Margins | 0.0 |
| Quick Ratio | 5.644 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.008899987 |
| Regular Market Change Percent | -2.7899647 |
| Regular Market Day High | 0.3189 |
| Regular Market Day Low | 0.2974 |
| Regular Market Day Range | 0.2974 - 0.3189 |
| Regular Market Open | 0.3112 |
| Regular Market Previous Close | 0.3152 |
| Regular Market Price | 0.3063 |
| Regular Market Time | 1,791,917,386 |
| Regular Market Volume | 1,017,494 |
| Return On Assets | -0.42462003 |
| Return On Equity | -0.67847997 |
| Revenue Per Share | 0.0 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 159,690,973 |
| Shares Percent Shares Out | 0.0168 |
| Shares Short | 2,678,406 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,764,977 |
| Short Name | Mereo BioPharma Group plc |
| Short Percent Of Float | 0.020599999 |
| Short Ratio | 1.42 |
| Source Interval | 15 |
| Symbol | MREO |
| Target High Price | 3.0053558 |
| Target Low Price | 0.98101604 |
| Target Mean Price | 1.9710467 |
| Target Median Price | 1.9434721 |
| Total Cash | 30,118,000 |
| Total Cash Per Share | 0.189 |
| Total Debt | 1,030,000 |
| Total Revenue | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.364005 |
| Two Hundred Day Average Change | -0.057704985 |
| Two Hundred Day Average Change Percent | -0.158528 |
| Type Disp | Equity |
| Volume | 1,017,494 |
| Website | https://www.mereobiopharma.com |
| Zip | W1G 0QF |